Stefanie Hartford is an Associate in the firm's Business Law department. She joined Goodwin in 2021. Stefanie is admitted to practice in Massachusetts only; her application to the New York bar is pending. She is working under the supervision of the partners at Goodwin.
Representative Matters
- Ikena Oncology Inc.’s (Nasdaq: IKNA) acquisition of Pionyr Immunotherapeutics in an all-stock transaction and contingent value rights (CVRs)
- Scholar Rock Holding Corporation (Nasdaq: SRRK) in its $300 million follow-on offering
- AVROBIO, Inc. (Nasdaq: AVRO) in its reverse merger with Tectonic Therapeutic, Inc., including contingent value rights and the concurrent private placement financing
- AVROBIO, Inc. (Nasdaq: AVRO) in its sale of its Cystinosis gene therapy program for $87.5 million to Novartis (NYSE: NVS)
- Aura Biosciences, Inc. (Nasdaq: AURA) in its $99 million follow-on offering
- Ikena Oncology, Inc. (Nasdaq: IKNA) in its $40 million underwritten offering
- Aura Biosciences, Inc. (Nasdaq: AURA) in its $80.4 million follow-on offering
- Mariana Oncology, Inc. in its $175 million Series B financing
Professional Activities
While attending Boston University School of Law, Stefanie was a note editor for the Journal of Science and Technology Law. She also served as a Legal Writing Fellow for the First Year Legal Writing Program. During her final year of law school, she participated in the Startup Law Clinic, providing legal counsel to Boston University and MIT student entrepreneurs on a variety of legal issues faced by early-stage business ventures.
Stefanie joined Goodwin as a summer associate in 2021.
Credentials
Education
JD2022
Boston University School of Law
BS2018
Boston University
BA2018
Boston University
Admissions
Bars
- Massachusetts